Yang YH - Search Results

1

Oleandrin enhances radiotherapy sensitivity in lung cancer by inhibiting the ATM/ATR-mediated DNA damage response.

Wu Q, Liu X, Wang LM, Yang YH, Pan LF, Zhang JJ, Wang YQ, Yao QH, Ma SL, Zhang SR. Wu Q, et al. Among authors: yang yh. Phytother Res. 2024 Aug;38(8):4151-4167. doi: 10.1002/ptr.8237. Epub 2024 Jun 22. Phytother Res. 2024. PMID: 39136618

2

SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.

Zhang J, Wu Q, Zhu L, Xie S, Tu L, Yang Y, Wu K, Zhao Y, Wang Y, Xu Y, Chen X, Ma S, Zhang S. Zhang J, et al. Cancer Lett. 2022 Jan 1;524:268-283. doi: 10.1016/j.canlet.2021.10.001. Epub 2021 Oct 11. Cancer Lett. 2022. PMID: 34648881 Free article.

3

CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway.

Zhang J, Pan L, Zhang S, Yang Y, Liang J, Ma S, Wu Q. Zhang J, et al. Clin Transl Oncol. 2023 Dec;25(12):3527-3540. doi: 10.1007/s12094-023-03222-5. Epub 2023 May 30. Clin Transl Oncol. 2023. PMID: 37249759

4

Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022) 268-283].

Zhang J, Wu Q, Zhu L, Xie S, Tu L, Yang Y, Wu K, Zhao Y, Wang Y, Xu Y, Chen X, Ma S, Zhang S. Zhang J, et al. Cancer Lett. 2025 Feb 1;610:217337. doi: 10.1016/j.canlet.2024.217337. Epub 2024 Nov 24. Cancer Lett. 2025. PMID: 39581824 Free article. No abstract available.

5

Upregulation of CoQ shifts ferroptosis dependence from GPX4 to FSP1 in acquired radioresistance.

Lin X, Zhang Q, Li Q, Deng J, Shen S, Tang M, Ye X, Ji C, Yang Y, Chen Y, Zeng L, Zhao J, Kouwenhoven MBN, Lucero-Prisno DE 3rd, Huang J, Li Y, Zhang B, Hu J. Lin X, et al. Drug Resist Updat. 2024 Mar;73:101032. doi: 10.1016/j.drup.2023.101032. Epub 2023 Dec 9. Drug Resist Updat. 2024. PMID: 38198846 Free article.

6

DSCC1 interacts with HSP90AB1 and promotes the progression of lung adenocarcinoma via regulating ER stress.

Lin X, Liu YH, Zhang HQ, Wu LW, Li Q, Deng J, Zhang Q, Yang Y, Zhang C, Li YL, Hu J. Lin X, et al. Among authors: yang y. Cancer Cell Int. 2023 Sep 23;23(1):208. doi: 10.1186/s12935-023-03047-w. Cancer Cell Int. 2023. PMID: 37742009 Free PMC article.

7

NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.

Zhang Z, Song B, Wei H, Liu Y, Zhang W, Yang Y, Sun B. Zhang Z, et al. Drug Resist Updat. 2024 Mar;73:101040. doi: 10.1016/j.drup.2023.101040. Epub 2024 Jan 9. Drug Resist Updat. 2024. PMID: 38228036

8

Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA-IIIB non-small-cell lung cancer in real-world practice.

Liu J, Huang X, Yang Y, Lv W, Wang Y, Xia P, Hu J. Liu J, et al. BMC Pulm Med. 2024 Nov 29;24(1):592. doi: 10.1186/s12890-024-03417-8. BMC Pulm Med. 2024. PMID: 39614293 Free PMC article.

9

Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.

Yao J, Pan S, Fan X, Jiang X, Yang Y, Jin J, Liu Y. Yao J, et al. J Chemother. 2020 Jul;32(4):202-207. doi: 10.1080/1120009X.2020.1746886. Epub 2020 Apr 11. J Chemother. 2020. PMID: 32281493

10

Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?

Liu J, Zhu L, Huang X, Lu Z, Wang Y, Yang Y, Ye J, Gu C, Lv W, Zhang C, Hu J. Liu J, et al. J Cancer Res Clin Oncol. 2024 Mar 27;150(3):161. doi: 10.1007/s00432-024-05696-4. J Cancer Res Clin Oncol. 2024. PMID: 38536527 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,919 results

Search Page

Filters